Express News | Aerovate Therapeutics Shares Are Trading Higher After the Company Announced It Is Exploring Strategic Alternatives
Express News | Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction
Express News | Aerovate Therapeutics - Wedbush Pacgrow Engaged as Exclusive Advisor
Express News | Aerovate Therapeutics Inc - to Conduct Strategic Alternatives Review
Express News | Aerovate Therapeutics to Explore Strategic Alternatives
Aerovate's Catastrophic Year: Failed PAH Drug Trial Leads To Mass Layoffs
Express News | Aerovate Therapeutics Inc - in Connection With Workforce Reduction Plan, Company Estimates That It Will Be Incurring Costs of Approximately $5.6 Mln
Express News | Aerovate Therapeutics Inc: Initiated First Wave of Its Workforce Reduction Plan by Notifying 39 Individuals, or 78% of Company's Workforce
Express News | Aerovate Therapeutics Inc: Under Workforce Reduction Plan, Company Intends That Nearly All of Its Workforce Will Be Terminated in Coming Months
Express News | Aerovate Therapeutics Inc: On June 25, Determined to Implement a Reduction of Company's Workforce
Express News | Watching Aerovate Therapeutics; Shares Moving Higher After RA Cap Management Buys 928,110 Shares
Aerovate(AVTE.US) 10% Shareholder Buys US$1.55 Million in Common Stock
Aerovate Therapeutics Price Target Cut to $2.00/Share From $27.00 by Evercore ISI Group
Guggenheim Downgrades Aerovate Therapeutics to Neutral
Aerovate Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Express News | Wells Fargo Downgrades Aerovate Therapeutics to Equal-Weight, Lowers Price Target to $2
A Quick Look at Today's Ratings for Aerovate(AVTE.US), With a Forecast Between $2 to $101
Aerovate Therapeutics Shares Are Trading Lower After TD Cowen Downgraded the Stock From Buy to Hold.
Express News | Aerovate Therapeutics Inc : Guggenheim Cuts to Neutral
Express News | Aerovate Therapeutics Inc : TD Cowen Cuts to Hold From Buy